Venture Capital: GreenLight Biosciences Notches $102M to Expand RNA-based Products
RNA products can play a salutary role in both life and crop sciences.
GreenLight Biosciences, which is pioneering technology to create cell-free, high-performing natural RNA products, announced its raise of $102 million in an oversubscribed Series D funding round led by Chinese investment firm Morningside Ventures. (BOSTINNO)
S2G Ventures, Coromorant Asset Management, Continental Grain Company, Fall Line Capital, Tao Capital Partners, Baird Venture Partners, MLS Capital Fund II, Lewis and Clark AgriFood, and Lupa Systems also participated.
The importance of RNA
Ribonucleic acid (RNA) is a natural molecule that controls the biological processes in all living things. RNA-based products can be immensely useful in the protection of crops from pests and the fight against diseases that afflict human beings.
Unfortunately, because of their high cost, RNA-based products were commercially unviable until recently.
Greenlight has patented GreenWorx, a cell-free bioprocessing platform for the production of RNA products at a much lower cost, permitting commercialization. These products are useful for both for plant and life sciences.
For example, GreenLight has held field trials targeting the pest known as the Colorado potato beetle. The beetle has become resistant to many insecticides. However, even when effective, insecticides damage the surrounding ecosystem. Not so GreenLight’s RNA-based product – it targets the beetle and nothing else and weakens it naturally.
GreenLight and COVID-19
These methods can be carried over to life sciences, too.
Earlier this month, GreenLight raised an additional $17 million from new and existing investors, including Malaysian private investment company Xeraya Capital, Baird Capital, and global investment company Flu Lab.
GreenLight will use the funds to establish a scaled process for the clinical development and production of billions of doses of COVID-19 vaccine using GreenLight’s proprietary technology.
“It’s an investment toward the world having access to an affordable COVID-19 vaccine. A bet that mRNA will play an important part in human vaccines,” Xeraya Capital CEO Fares Zahir said.
GreenLight, too, is developing several RNA-based coronavirus vaccine candidates. Moreover, its mRNA vaccine production platform can scale the development of not only GreenLight’s own vaccines but of others as well.
Use of the new $102 million fundraising
The latest raising of $102 million will fund GreenLight’s development of new RNA-based therapeutics for human health. The company will also use the funds for the development and commercialization of products for crop protection.
“GreenLight Biosciences’ manufacturing technology can address critical pain points for RNA supply in both agriculture and human health,” said Jason Dinges of Morningside Ventures. “RNA-based products represent an opportunity for innovation in both human therapeutics as well as safe, environmentally friendly crop protection.
Image credit of an RNA Strand: Flickr
Latest Alternative Investment News
PAYFAZZ, an Indonesian fintech start-up, scooped up $ 53 million in a Series B funding round led by B Capital Group and Insignia Ventures Partners. Existing investors Tiger Global Management,…
Back in February 2020, researchers at BenevolentAI, a British company that uses artificial intelligence in drug discovery, were sifting through its drugs database. The objective: to find one that could…
Digital Assets: Cubans Take to Cryptos Amidst Food Shortage; Over 2,500 Austrian Merchants to Accept Cryptos
Cuba is grappling with a national food crisis stemming from Venezuela’s decision to cut off its aid to the country. Problems have been compounded by the nonavailability, due to the…
Uber Technologies Inc. (NYSE: UBER) is acquiring food delivery start-up Postmates for $ 2.65 billion in an all-stock deal, according to reports by Bloomberg and the New York Times. Uber…